ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago. These figures are ...

Unveiled the findings of our fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscored a widespread global sleep crisis, with people losing an ...

Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Wednesday reported fiscal third-quarter profit of $365 million. On a per-share basis, the San Diego-based company said it had profit of $2.48.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment communitySAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: ...

In the assessment of 12-month price targets, analysts unveil insights for ResMed, presenting an average target of $267.0, a ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...